Catalyst Dossier · compiled by CeliA 🧫

aTyr Pharma, Inc. (LIFE)

Insurance Agents, Brokers & Service · market cap $352M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
ATYR1940	Phase 2	Limb-Girdle Muscular Dystrophies
efzofitimod 450 mg	Phase 2	Interstitial Lung Disease
Efzofitimod 3 mg/kg	Phase 3	Pulmonary Sarcoidosis
Efzofitimod 1 mg/kg	Phase 2	SARS-CoV-2 (COVID-19) Severe Pneumonia

Price & technical context

3-month

+79.4%

6-month

—

12-month

—

52-wk range

$9.85–$30.59

vs 50-day MA

-3.9%

vs 200-day MA

—

Realized vol

101.8%

Max drawdown

-50.1%

Daily closes through 2026-06-24. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for LIFE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.